Theravance Biopharma, Inc.
DE ˙ DB ˙ KYG8807B1068
13,60 € ↑0,30 (2,26%)
2026-06-04
CENA AKCJI
SecurityDE:0TB / Theravance Biopharma, Inc.
InstitutionJanus Henderson Group Plc
Latest Disclosed Ownership378,978 shares
Latest Disclosed Value $ 6,151,331
Janus Henderson Group Plc reports 5.37% decrease in ownership of 0TB / Theravance Biopharma, Inc.

On May 18, 2026 - Janus Henderson Group Plc filed a 13F-HR/A form disclosing ownership of 378,978 shares of Theravance Biopharma, Inc. (DE:0TB) valued at $5,002,510 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 400,496 shares of Theravance Biopharma, Inc.. This represents a change in shares of -5.37% during the quarter. The current value of the position is $5,154,101 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-18 2026-03-31 13F/A-1 THERAVANCE BIOPHARMA COM G8807B106 378,978 -21,518 -5.37 6,151 -17.91 0.0010
2026-05-15 2026-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 378,978 -21,518 -5.37 6,151 -17.91 0.0011
2026-02-17 2025-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 400,496 273,288 214.84 7,493 303.50 0.0034
2025-11-14 2025-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 127,208 127,208 1,857 0.0008
2025-05-15 2025-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 0 -24,666 -100.00 0 -100.00
2025-02-14 2024-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 24,666 0 0.00 232 16.58 0.0001
2024-11-14 2024-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 24,666 0 0.00 199 -4.33 0.0001
2024-08-14 2024-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 24,666 -237 -0.95 209 -6.73 0.0001
2024-05-15 2024-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 24,903 6 0.02 223 -20.07 0.0001
2024-02-14 2023-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 24,897 -40 -0.16 280 30.37 0.0002
2023-11-14 2023-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 24,937 -51 -0.20 215 -17.05 0.0001
2023-08-14 2023-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 24,988 -55 -0.22 259 -4.80 0.0002
2023-05-15 2023-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 25,043 14,055 127.91 272 120.33 0.0002
2023-02-14 2022-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 10,988 -1 -0.01 123 9.82 0.0001
2023-01-13 2022-09-30 13F/A-1 THERAVANCE BIOPHARMA COM G8807B106 10,989 -85 -0.77 112 12.00 0.0001
2022-11-14 2022-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 10,989 -85 112 0.0000
2022-08-15 2022-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 11,074 78 0.71 100 -4.76 0.0001
2022-05-16 2022-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 10,996 -3 -0.03 105 -13.93 0.0001
2022-02-14 2021-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 10,999 10,999 122 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.